TLP Group’s Abiomed Inc ABMD Stock Holding History

TLP Group’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-84	Closed	-$16K	–	674
2017 Q4	$16K	Buy	+84	New	+$15.7K	0.01%	307

Other funds holding ABMD

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

TLP Group's ABMD Position: Q1 2018 in Review

TLP Group sold out of Abiomed Inc (ABMD) in Q1 2018, closing a stake of 84 shares — an estimated $16K sold.

TLP Group first reported a position in ABMD in Q4 2017 and held it in 1 quarter. The position peaked at $16K in Q4 2017. 405 funds tracked by Wall St. Rank hold ABMD as of Q1 2018.

TLP Group reported no remaining Abiomed Inc position as of Q1 2018 after selling out during the quarter.
TLP Group sold 84 Abiomed Inc shares in Q1 2018, an estimated $16K.
TLP Group first reported a position in Abiomed Inc in Q4 2017 and held it in 1 quarter.
TLP Group's Abiomed Inc position peaked at $16K in Q4 2017.
405 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2018.

Based on TLP Group's 13F filing for Q1 2018, filed 16 May 2018.